Despite sclerostin being a useful marker in bone disease, the lack of correlation with PTH levels and the apparently opposite effect in CKD conditions compared to an isolated alteration in PTH concentration suggest the possibility of an intermediate regulatory level. This evidence concerns the gene PTH and chronic kidney disease.